Related Experiment Video
Updated: Jul 19, 2026
Preclinical Cardiac Electrophysiology Assessment by Dual Voltage and Calcium Optical Mapping of Human Organotypic Cardiac Slices
Published on: June 16, 2020
The human embryonic stem cell-derived cardiomyocyte as a pharmacological model
Sian E Harding1, Nadire N Ali, Marta Brito-Martins
1Imperial College London, Dovehouse Street, London SW3 6LY, UK. sian.harding@imperial.ac.uk
Human embryonic stem cell-derived cardiomyocytes (hESCM) offer a promising model for cardiac research and drug screening. These cells provide a viable alternative to current systems, enabling better pharmacological and physiological studies.
Area of Science:
- Cardiology
- Stem Cell Biology
- Pharmacology
Background:
- Human embryonic stem cells (hESCs) are being explored for tissue repair and drug screening.
- Current cardiac models are suboptimal for pharmacological and physiological studies.
- hESCs can differentiate into cardiomyocytes (hESCM), offering advantages over primary cells.
Purpose of the Study:
- To review methods for obtaining and purifying hESCM.
- To compare hESCM characteristics with primary cardiomyocytes.
- To evaluate hESCM for drug screening and basic research.
Main Methods:
- Methodologies for hESCM derivation and purification.
- Characterization of hESCM morphology, contractility, and electrophysiology.
- Pharmacological studies on adrenoceptors and muscarinic receptors.
- Assessment of repolarization using multielectrode arrays (MEA).
Main Results:
- Stable and reproducible responses observed in pharmacological studies.
- Prolongation of repolarization detected using hESCM on MEA.
- hESCM exhibit characteristics comparable to primary cardiomyocytes.
Conclusions:
- hESCM present a valuable model for basic cardiac research.
- hESCM show significant potential for pharmaceutical screening of cardiac compounds.
- Further development of hESCM is crucial for clinical applications.
More Related Videos
10:30Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: August 4, 2022
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022